BORIANI, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 80.599
EU - Europa 23.036
AS - Asia 12.230
OC - Oceania 316
SA - Sud America 216
AF - Africa 75
Continente sconosciuto - Info sul continente non disponibili 47
Totale 116.519
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 79.936
GB - Regno Unito 8.396
IT - Italia 4.632
CN - Cina 3.917
SG - Singapore 3.554
SE - Svezia 2.608
DE - Germania 2.590
HK - Hong Kong 1.950
TR - Turchia 1.829
UA - Ucraina 1.732
BG - Bulgaria 855
FI - Finlandia 509
FR - Francia 464
ID - Indonesia 449
BZ - Belize 400
AU - Australia 305
RU - Federazione Russa 289
IE - Irlanda 206
CA - Canada 181
NL - Olanda 159
PL - Polonia 117
IN - India 111
ES - Italia 103
BR - Brasile 102
JP - Giappone 84
LT - Lituania 75
BE - Belgio 67
MX - Messico 57
MY - Malesia 53
VN - Vietnam 40
CH - Svizzera 37
EU - Europa 36
IR - Iran 36
RO - Romania 36
CO - Colombia 30
CL - Cile 29
GR - Grecia 25
IL - Israele 25
GE - Georgia 24
TW - Taiwan 24
ZA - Sudafrica 23
CZ - Repubblica Ceca 22
AR - Argentina 21
AT - Austria 17
PT - Portogallo 17
EG - Egitto 16
KR - Corea 16
TH - Thailandia 16
PH - Filippine 15
PK - Pakistan 15
RS - Serbia 15
IQ - Iraq 14
DK - Danimarca 12
HU - Ungheria 12
CU - Cuba 11
NZ - Nuova Zelanda 11
PE - Perù 11
A2 - ???statistics.table.value.countryCode.A2??? 9
NO - Norvegia 8
BD - Bangladesh 7
EC - Ecuador 7
KZ - Kazakistan 7
SK - Slovacchia (Repubblica Slovacca) 7
VE - Venezuela 7
MD - Moldavia 6
TN - Tunisia 6
DO - Repubblica Dominicana 5
GH - Ghana 5
KE - Kenya 5
SA - Arabia Saudita 5
SI - Slovenia 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
BO - Bolivia 4
CR - Costa Rica 4
DZ - Algeria 4
NP - Nepal 4
UG - Uganda 4
UZ - Uzbekistan 4
AL - Albania 3
BT - Bhutan 3
JO - Giordania 3
LK - Sri Lanka 3
MA - Marocco 3
MK - Macedonia 3
NG - Nigeria 3
PS - Palestinian Territory 3
QA - Qatar 3
UY - Uruguay 3
BA - Bosnia-Erzegovina 2
EE - Estonia 2
HR - Croazia 2
JM - Giamaica 2
LA - Repubblica Popolare Democratica del Laos 2
LU - Lussemburgo 2
PA - Panama 2
PY - Paraguay 2
SC - Seychelles 2
TZ - Tanzania 2
AP - ???statistics.table.value.countryCode.AP??? 1
Totale 116.508
Salva come PNG Salva come JPEG
Città #
Fairfield 12.851
Woodbridge 7.524
Southend 7.258
Santa Clara 7.050
Houston 5.830
Ashburn 5.773
Seattle 4.941
Cambridge 4.149
Chandler 4.145
Wilmington 4.073
Jacksonville 3.635
Singapore 2.916
Ann Arbor 2.815
Dearborn 2.335
Hong Kong 1.898
Nyköping 1.463
Modena 1.427
Beijing 1.321
San Diego 1.244
Izmir 1.214
New York 1.106
Princeton 893
Sofia 851
San Jose 847
Eugene 729
Jakarta 438
Belize City 400
London 400
Helsinki 337
Dallas 325
Milan 297
Falls Church 256
Boardman 216
Rome 206
Bologna 197
Fremont 187
Chicago 184
Dublin 183
Shanghai 175
Saint Louis 169
Perth 168
Norwalk 163
Las Vegas 139
Albuquerque 133
Hefei 128
Redwood City 120
Kunming 116
Atlanta 111
Moscow 111
Nanjing 110
Kilburn 100
Guangzhou 96
Columbus 94
Munich 90
Grafing 75
Toronto 73
Jinan 68
Chiswick 61
Florence 60
Naples 60
Amsterdam 58
Sydney 57
Lappeenranta 54
Brussels 51
Prescot 51
Nanchang 49
Hounslow 48
Turin 46
Saint Petersburg 45
Sergii 43
Parma 42
Fuzhou 41
Wuhan 40
Des Moines 36
Philadelphia 36
Los Angeles 35
San Giuliano Milanese 35
Reggio Emilia 33
Shenyang 33
Tokyo 33
Zhengzhou 32
Bremen 31
Ottawa 31
Paris 31
San Francisco 31
Acton 29
Central 29
Frankfurt am Main 28
Islington 28
Esslingen am Neckar 27
Milwaukee 27
Verona 27
Wandsworth 25
Changsha 24
Dong Ket 24
Forlimpopoli 24
Warsaw 24
Chengdu 22
Chongqing 22
Mountain View 22
Totale 95.738
Salva come PNG Salva come JPEG
Nome #
Long-Term Implications of Atrial Fibrillation in Patients With Degenerative Mitral Regurgitation 567
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC (Eur Heart J (2021) 42 (373–498) DOI: 10.1093/eurheartj/ehaa612) 389
La sindrome da pacemaker. 367
Atrial Fibrillation in the Setting of Acute Pneumonia: Not a Secondary Arrhythmia 346
Linee guida AIAC all'impianto di pacemaker, dispositivi per la resincronizzazione cardiaca, defibrillatori automatici e loop recorder. Update 2011. 327
Registro Italiano Pacemaker e Defibrillatori: Bollettino Periodico 2016 Associazione Italiana di Aritmologia e Cardiostimolazione 307
Screening for atrial fibrillation: A Report of the AF-SCREEN International Collaboration 290
The future of continuing medical education: the roles of medical professional societies and the health care industry: Position paper prepared with contributions from the European Society of Cardiology Committees for Advocacy, Education and Industry Relations, Endorsed by the Board of the European Society of Cardiology 277
Prevalence and clinical significance of left bundle branch block according to classical or strict definition criteria in permanent pacemaker patients 269
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial 268
2018 EHRA expert consensus statement on lead extraction: Recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: Endorsed by APHRS/HRS/LAHRS 259
Guía de práctica clínica de la ESC 2013 sobre estimulación cardiaca y terapia de resincronización cardiaca 253
Clinically guided pacemaker choice and setting: pacemaker expert programming study 244
Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol 232
Implantable cardioverter-defibrillator–computed respiratory disturbance index accurately identifies severe sleep apnea: The DASAP-HF study 231
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA) 229
The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Executive summary 225
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report 225
108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands. 224
Role of the tricuspid regurgitation after mitraclip and transcatheter aortic valve implantation: a systematic review and meta-analysis 223
Health economics and the European Heart Rhythm Association. 222
Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation 222
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 221
'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: The EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry 220
Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations 218
P wave dispersion and short-term vs. late atrial fibrillation recurrences after cardioversion 218
Home care for heart failure: can caregiver education prevent hospital admissions? A randomized trial in primary care 216
QRS interval time-related changes and prognosis in heart failure 212
Letter by Gasparini and Boriani Regarding Article, "Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation: Results From the Resynchronization for Ambulatory Heart Failure Trial (RAFT)" 212
Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden 210
Cardiac device therapy in patients with left ventricular dysfunction and heart failure: ‘real-world’ data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital) 208
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing 208
Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry 208
Prediction of cardiac resynchronization therapy response: value of calibrated integrated backscatter imaging. 206
The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden 206
Emery-Dreifuss Muscular Dystrophy-Associated Mutant Forms of Lamin A Recruit the Stress Responsive Protein Ankrd2 into the Nucleus, Affecting the Cellular Response to Oxidative Stress 202
QRS pattern and improvement in right and left ventricular function after cardiac resynchronization therapy: a radionuclide study 202
Risk stratification of cardiovascular and heart failure hospitalizations using integrated device diagnostics in patients with a cardiac resynchronization therapy defibrillator 202
Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF 201
Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation 200
Remote Monitoring of Patients with an Implanted Device and Patients' Outcomes: The Potential for "Win-Win" Dynamics. 200
EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation 200
12-year Temporal Trend in Referral Pattern and Test Results of Stress Echocardiography in a Tertiary Care Referral Center with Moderate Volume Activities and Cath-lab Facility 200
'Real-world' atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase 199
Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples 199
Inappropriate shock for myopotential over-sensing in a patient with subcutaneous ICD 198
Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation 198
The wearable cardioverter-defibrillator: Current technology and evolving indications 198
Elevated TGF β2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes 197
Cardiac resynchronization therapy: is systole all that matters? 196
Validation of a simple risk stratification tool for patients implanted with Cardiac Resynchronization Therapy: The VALID-CRT risk score 196
Beta-blocker treatment guided by head-up tilt test in neurally mediated syncope 196
Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. 195
The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) Randomized Controlled Trial: Phase 1 Results on Dynamics of Early Intervention With Remote Monitoring 195
Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes 194
New classification of geometric patterns considering left ventricular volume in patients with chronic aortic valve regurgitation: Prevalence and association with adverse cardiovascular outcomes 194
Decrease in patient radiation exposure by a tantalum filter during electrophysiological procedures. 193
Health care cost analysis of enhanced pacing modalities in bradycardia patients: Portuguese case study on the results of the MINERVA trial 193
Cardiac resynchronization therapy in the real world: need to focus on implant rates, patient selection, co-morbidities, type of devices, and complications 193
Randomized comparison between Ramp and Burst+ atrial antitachycardia pacing therapies in patients suffering from sinus node disease and atrial fibrillation and implanted with a DDDRP device. 193
Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry 193
Cardiac resynchronization therapy in the real world: need to upgrade outcome research 193
Management of Phrenic Stimulation in CRT Patients over the Long Term: Still an Unmet Need ? 192
Asymptomatic lone atrial fibrillation - how can we detect the arrhythmia? 192
A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. 192
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary 192
Implantable dual-chamber defibrillator for the selective treatment of spontaneous atrial and ventricular arrhythmias: arrhythmia incidence and device performance. 191
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 191
Atrial evoked response integral for automatic capture verification in atrial pacing 191
Extending survival by reducing sudden death with implantable cardioverter-defibrillators: a challenging clinical issue in non-ischaemic and ischaemic cardiomyopathies 191
Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants 191
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 190
The QRS interval in patients treated with resynchronization therapy: which value? 190
New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial 190
Ventricular fibrillation during sleep in an adolescent with hypertrophic cardiomyopathy: the difficulty of risk stratification and the power of the cardioverter-defibrillator 190
Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: Results of markov modelling in a european population 189
Far-field R wave oversensing in dual-chamber pacemakers designed for atrial arrhythmia management: effect of pacing site and lead tip to ring distance 188
Effect of high-pass filtering on ECG signal on the analysis of patients prone to atrial fibrillation 188
Rhythm discrimination by rate branch and QRS morphology in dual chamber implantable cardioverter defibrillators 188
'Pill-in-the-pocket' treatment for recent-onset atrial fibrillation [4] 188
Heart failure after myocardial revascularization: Risk markers 187
Cardiac resynchronization therapy: effects on left and right ventricular ejection fraction during exercise. 187
Combined use of morphology discrimination, sudden onset, and stability as discriminating algorithms in single chamber cardioverter defibrillators 187
Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy 187
Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. 187
Occupational radiation exposure in the electrophysiology laboratory with a focus on personnel with reproductive potential and during pregnancy: A European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS) 187
Reducing unnecessary right ventricular pacing with the managed ventricular pacing mode in patients with sinus node disease and AV block. 187
Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling 186
Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy 186
The empowerment of translational research: lessons from laminopathies 186
Oral loading of propafenone: restoring its role before restoring rhythm 186
Cardiac tachyarrhythmias and patient values and preferences for their management: The European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 186
European Society of Cardiology-Proposed Diagnostic Echocardiographic Algorithm in Elective Patients with Clinical Suspicion of Infective Endocarditis: Diagnostic Yield and Prognostic Implications in Clinical Practice 186
Role of ventricular Autocapture function in increasing longevity of DDDR pacemakers: a prospective study. 185
Cardiac resynchronization therapy and electrical storm: results of the OBSERVational registry on long-term outcome of ICD patients (OBSERVO-ICD) 185
Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry 185
Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action 185
Cardiac resynchronization by pacing: an electrical treatment of heart failure 184
Cardiac resynchronization and implantable cardioverter defibrillator therapy: Preliminary results from the InSync Implantable Cardioverter Defibrillator Italian Registry 184
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 184
Totale 21.420
Salva come PNG Salva come JPEG
Categoria #
all - tutte 537.279
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 537.279
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202018.864 0 0 0 0 0 4.693 5.403 2.518 3.021 1.172 1.531 526
2020/202122.437 1.993 841 2.000 2.486 2.603 1.348 2.848 2.882 1.051 2.005 1.309 1.071
2021/202215.465 664 1.848 1.677 712 427 1.286 887 786 1.655 1.369 2.411 1.743
2022/202311.536 1.660 974 714 826 1.469 1.536 259 1.187 1.758 206 597 350
2023/20249.853 393 632 435 803 2.283 1.440 447 1.696 223 253 327 921
2024/202513.061 1.151 386 730 1.788 4.911 4.095 0 0 0 0 0 0
Totale 119.639